Gastric adenocarcinoma prognosis-related molecular marker combination and gastric adenocarcinoma prognosis assessment model

By constructing a gastric adenocarcinoma prognostic evaluation model based on GRIK1, ROS1, PCDHGA4, OLFM4, ATP13A5, MYO3B, and IL37, the problems of early diagnosis and prognostic evaluation of gastric adenocarcinoma are solved, more accurate prognostic risk prediction and treatment guidance are achieved, and patients are improved Survival rate.

CN118782159BActive Publication Date: 2024-12-03HANGZHOU INSTITUTE OF MEDICAL SCIENCES CHINESE ACADEMY OF SCIENCES
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411262128.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-12-03
Estimated Expiration
2044-09-10

AI Technical Summary

Technical Problem

The prior art is difficult to effectively predict the early diagnosis and prognosis evaluation of gastric adenocarcinoma, resulting in the 5-year survival rate of gastric cancer patients is only 25% to 30%, and new targeted treatment methods are urgently needed.

Method used

A combination of molecular markers related to gastric adenocarcinoma prognosis is proposed, including seven genes: GRIK1, ROS1, PCDHGA4, OLFM4, ATP13A5, MYO3B and IL37. By detecting the expression of these genes and calculating the risk score, a gastric adenocarcinoma prognosis evaluation model was constructed. , used to predict the prognostic risk of patients.

Benefits of technology

Through the optimization of Lasso regression algorithm, this model significantly improves the accuracy of gastric adenocarcinoma prognosis prediction, helps to intervene and guide clinical treatment in advance, and significantly improves the 5-year survival rate of patients with gastric adenocarcinoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118782159B_ABST
    Figure CN118782159B_ABST
Patent Text Reader

Abstract

The present invention discloses a combination of molecular markers related to the prognosis of gastric adenocarcinoma and a prognosis evaluation model for gastric adenocarcinoma. The present invention integrates the overall survival data of 99 gastric adenocarcinoma patients from Zhejiang Cancer Hospital, screens genes GRIK1, ROS1, PCDHGA4, OLFM4, ATP13A5, MYO3B, and IL37 as gastric adenocarcinoma prognosis markers, and constructs a risk assessment model based on GRIK1, ROS1, PCDHGA4, OLFM4, ATP13A5, MYO3B, and IL37, and verifies the accuracy of the model. The present invention helps to better predict the prognosis of gastric adenocarcinoma patients, effectively assess the prognosis risk of different patients, intervene early, and bring great help to guide the clinical treatment of the disease, thereby improving the 5-year survival rate of gastric adenocarcinoma patients. The risk assessment model of the present invention has high prediction accuracy and universality, which is significantly better than other gastric adenocarcinoma prognosis methods in the prior art, and is also significantly better than other models constructed during the research process.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedical technology, and in particular relates to a combination of molecular markers related to gastric adenocarcinoma prognosis and a gastric adenocarcinoma prognosis evaluation model. Background Art

[0002] Gastric cancer is one of the most common malignant tumors of the digestive tract in clinical practice, and its mortality rate ranks first among digestive system tumors. Gastric adenocarcinoma is the most common histological type of gastric cancer, accounting for about 95% of all gastric cancers. At present, early gastric cancer is mainly treated by endoscopy and surgery, and the conventional treatment for advanced gastric cancer is surgery combined with postoperative chemotherapy; for patients with recurrence or inoperable surgery, chemotherapy is the only treatment to prolong their lives. Early diagnosis and early treatment are of great significance to improving the quality of life and prognosis of gastric cancer patients. However, due to the complex pathogenesis, the resistance of patients to chemotherapy, and the metastasis and recurrence of advanced gastric cancer, the 5-year survival rate of gastric cancer patients is only 25%~30%. Therefore, new targeted therapies are urgently needed. Exploring the mechanism of occurrence and metastasis of gastric adenocarcinoma at the molecular level, laying the foundation for early diagnosis and prognosis evaluation of gastric adenocarcinoma, has important scientific and social significance. We aim to find new and effective molecular markers for the prognosis of gastric adenocarcinoma to provide a basis for further diagnosis and treatment of gastric adenocarcinoma patients.

[0003] GRIK1: The expression product of glutamate ionotropic receptor kainate type subunit 1 Gene (GRIK1) belongs to the kainate receptor (KAR) of glutamate receptors. It is composed of four subunits and acts as a ligand-activated ion channel. KAR regulates the release of glutamate and GABA. KAR plays an important role in neurological and psychiatric diseases such as epilepsy, ischemic brain injury, stress, anxiety, and depression. Studies have shown that hippocampal KAR containing GRIK1 subunits is mainly expressed in interneurons, reducing GABA release and increasing the excitability of hippocampal autonomic neurons. In addition, glutamate release can be inhibited by presynaptic inhibition mediated by adenosine and GABAB receptor activation. In terms of tumor-related aspects, studies have shown that GRIK1 plays a core role in the malignant phenotype of various types of tumors (such as breast cancer and recurrent glioblastoma), and is associated with hepatocellular carcinoma induced by hepatitis B. In addition, GRIK1 overexpression can significantly inhibit the proliferation, migration and invasion of colorectal cancer (CRC) cells.

[0004] ROS1: The protein encoded by ROS proto-oncogene 1 (ROS1) belongs to the receptor tyrosine kinase (RTK) of the insulin receptor family. It is a type I integral membrane protein with tyrosine kinase activity. It can act as a growth or differentiation factor receptor, stimulate signal transduction through the RAS-RAF-MEK-ERK, PI3K-AKT-mTOR and JAK-STAT3 pathways, and widely regulate cell survival, growth and proliferation. Carcinogenic mutations in the ROS1 gene will activate signals in its downstream pathways and drive the occurrence of tumors. Fusion is the main type of mutation in the ROS1 gene. Overexpression, mutation and amplification of the ROS1 gene have been found in many cancers, such as glioblastoma and meningioma, metastatic oral squamous cell carcinoma, breast cancer and soft tissue sarcoma. It is also a clear driver gene for non-small cell lung cancer (NSCLC) and is associated with poor prognosis. Studies have shown that ROS1 is upregulated in gastric cancer, and knockdown inhibits the activation of the PI3K / Akt signaling pathway, significantly inhibits gastric cancer cell growth, metastasis, and epithelial-mesenchymal transition, and induces cell apoptosis. In addition, ROS1 inhibitors can induce synthetic lethality in cancers associated with cadherin (CDH1) defects, providing a potential clinical treatment strategy for patients with diffuse gastric cancer (DGC) and breast cancer.

[0005] PCDHGA4: protocadherin gamma subfamily A 4 (PCDHGA4) is located in the q31 region of the long arm of human chromosome 5. The PCDHGA4 gene contains one exon, encoding a protein composed of 930 amino acid residues. It is a type I transmembrane protein that plays an important role in the development of the nervous system and is involved in the recognition, adhesion and signal transduction between neurons. Studies have shown that dysregulated PCDHGA4 expression may be associated with certain neurological diseases such as autism and schizophrenia. At the same time, the expression of the PCDHGA4 gene is regulated by epigenetic modifications, such as DNA methylation and histone modification. These epigenetic modifications affect the transcriptional activity of the gene and are related to the occurrence of some cancers.

[0006] OLFM4: The olfactomedin 4 (OLFM4) gene was originally cloned from human myeloblasts and was found to be selectively expressed in inflamed colon epithelial cells. This gene encodes a member of the olfactory receptor family. The encoded protein is an anti-apoptotic factor that promotes tumor growth and an extracellular matrix glycoprotein that promotes cell adhesion. Studies have shown that OLFM4 is highly expressed in a variety of tumors and plays a significant role in regulating gastric cancer cell proliferation and apoptosis. Knockdown of OLFM4 can significantly inhibit the proliferation, migration and invasion of gastric cancer cells. OLFM4 not only plays a key role in the occurrence and development of gastric cancer, but its expression level is also closely related to the prognosis of gastric cancer patients, and can be used as a potential candidate for gastric cancer prognostic markers.

[0007] ATP13A5: ATPase 13A5 (ATPase 13A5 Gene, ATP13A5) is located on 3q29 and encodes a member of the P5 subfamily of P-type transport ATPases. This family was first discovered in yeast, and studies have found that ATP13A5 is derived from the yeast homolog Yor291wp. At the same time, reports have shown that ATP13A5 is mainly expressed in the brain (including the brain, spinal cord, and retina) and the stomach. The functions of the related P5 atpase are as follows: transport of cargo proteins to the Golgi apparatus, glycosylation and cell wall biosynthesis, protein insertion direction control, HMGR degradation, and sensitivity to unfolded protein response (UPR) activators. It can also transport inorganic cations and lipids across the cell membrane, but its ion specificity is still unclear. It is currently found that this gene is a new type of brain pericyte-specific marker, associated with saliva-specific site-metabolites, and may also be related to the occurrence of Hailey disease.

[0008] MYO3B: Myosin III (Bmyosin IIIB Gene, MYO3B) is located on 2q31.1. MYO3B was first cloned from the human retina. It is expressed in the mouse retina, kidney, testis, brain, olfactory bulb and thymus. This gene encodes a class III myosin, which can selectively splice to result in multiple transcript variants encoding different isoforms. Studies have shown that the loss of MYO3A and MYO3B in mice can lead to severe deafness phenotypes, may play a role in the occurrence of Bardet-Biedl syndrome, and is a potential risk site for sleep bruxism. MYO3B or its homologs are associated with multiple phenotypes such as Mycobacterium bovis resistance in cattle, and are related to immune characteristics, especially immune characteristics to gastrointestinal nematodes, and may be an important gene causing obesity. At present, in the study of its relationship with tumor development and prognosis, we only know that it is related to the development of urinary system symptoms after radiotherapy for prostate cancer, and may serve as an antagonist for trastuzumab treatment of HER2+ cell lines.

[0009] IL37: Interleukin-37 (IL37) is an immune negative regulatory molecule discovered in 2000 and belongs to the IL-1 family. IL37 is expressed not only in a variety of immune cells, but also in cells of a variety of solid tissues and organs, including tumor cells. IL37 can inhibit the inflammatory response caused by adaptive immune response and innate immune response, and has been proven to be involved in the occurrence and development of a variety of tumors, exerting its anti-tumor effect in various ways such as inhibiting tumor proliferation and migration. The expression level of IL37 in a variety of tumors is correlated with the overall survival rate and tumor-free survival time of the tumor. Summary of the invention

[0010] In view of the above-mentioned deficiencies in the prior art, the present invention provides a gastric adenocarcinoma prognosis-related molecular marker combination and a gastric adenocarcinoma prognosis assessment model.

[0011] The present invention first provides a combination of molecular markers related to the prognosis of gastric adenocarcinoma, comprising GRIK1 , ROS1 , PCDHGA4 , OLFM4 , ATP13A5 , MYO3B and IL37 These 7 genes.

[0012] The present invention further provides the use of the gastric adenocarcinoma prognosis-related molecular marker combination as a detection marker in the preparation of a product for gastric adenocarcinoma prognosis risk prediction.

[0013] Preferably, the prognostic risk prediction of gastric adenocarcinoma comprises the following steps:

[0014] (1) Detection of gastric adenocarcinoma tumor tissue samples from the individual to be tested GRIK1 , ROS1 , PCDHGA4 , OLFM4 , ATP13A5 , MYO3B and IL37 The expression levels of these 7 genes;

[0015] (2) Substitute the expression value obtained in step (1) into the risk scoring formula to obtain the risk score, where the risk scoring formula is:

[0016] Risk score = -0.782a+0.592b+0.018c-5.710d+0.682e-0.047f+0.901g,

[0017] Among them, a is GRIK1 Gene expression in tumor tissues,

[0018] b is ROS1 Gene expression in tumor tissues,

[0019] c is PCDHGA4 Gene expression in tumor tissues,

[0020] d is OLFM4 Gene expression in tumor tissues,

[0021] e is ATP13A5 Gene expression in tumor tissues,

[0022] f is MYO3B Gene expression in tumor tissues,

[0023] g is IL37 Gene tumor tissue expression;

[0024] (3) The higher the patient risk score calculated in step (2), the worse the prognosis.

[0025] More preferably, in step (3), the median risk score of 0.036789 is used as a threshold, and those above the threshold are high risk, and those below the threshold are low risk, thereby predicting the prognosis of gastric cancer patients.

[0026] The expression level of gene tumor tissue is calculated as per kilobase per million reads (FPKM): FPKM is the number of reads mapped to the gene divided by the total number of reads, and normalized by considering the gene length, so that the expression levels of different genes and different samples can be compared, thus avoiding expression errors caused by different sequencing depths or gene length differences. The FPKM calculation formula is as follows:

[0027] ,

[0028] The present invention further provides the use of a reagent for detecting the gene expression level of the gastric adenocarcinoma prognosis-related molecular marker combination in the preparation of a gastric adenocarcinoma prognosis risk prediction product.

[0029] Preferably, the prognostic risk prediction of gastric adenocarcinoma comprises the following steps:

[0030] (1) Detection of gastric adenocarcinoma tumor tissue samples from the individual to be tested GRIK1 , ROS1 , PCDHGA4 , OLFM4 , ATP13A5 , MYO3B and IL37 The expression levels of these 7 genes;

[0031] (2) Substitute the expression value obtained in step (1) into the risk scoring formula to obtain the risk score, where the risk scoring formula is:

[0032] Risk score = -0.782a+0.592b+0.018c-5.710d+0.682e-0.047f+0.901g,

[0033] Among them, a is GRIK1 Gene expression in tumor tissues,

[0034] b is ROS1 Gene expression in tumor tissues,

[0035] c is PCDHGA4 Gene expression in tumor tissues,

[0036] d is OLFM4 Gene expression in tumor tissues,

[0037] e is ATP13A5 Gene expression in tumor tissues,

[0038] f is MYO3B Gene expression in tumor tissues,

[0039] g is IL37 Gene tumor tissue expression;

[0040] (3) The higher the patient risk score calculated in step (2), the worse the prognosis.

[0041] More preferably, in step (3), the median risk score of 0.036789 is used as a threshold, and those above the threshold are high risk, and those below the threshold are low risk, thereby predicting the prognosis of gastric cancer patients.

[0042] Gene tumor tissue expression was calculated as per kilobase per million reads (FPKM): FPKM is the number of reads mapped to a gene divided by the total number of reads, normalized to account for gene length.

[0043] The present invention also provides a gastric adenocarcinoma prognosis risk prediction product, comprising a reagent for detecting the gene expression level of the gastric adenocarcinoma prognosis-related molecular marker combination.

[0044] Preferably, the reagent is a reagent for detecting the expression level of each molecular marker.

[0045] More preferably, the reagent is a primer for detecting the expression level of each molecular marker.

[0046] The present invention also provides a gastric adenocarcinoma prognosis evaluation model, comprising a detection module, an analysis module and a result output module, wherein

[0047] Detection module: used to detect samples from individuals to be detected, and obtain the expression level of each gene in the gastric adenocarcinoma prognosis-related molecular marker combination in the samples;

[0048] Analysis module: used to analyze the expression of each gene detected by the detection module, and substitute the obtained expression value into the risk scoring formula to obtain the risk score, where the risk scoring formula is:

[0049] Risk score = -0.782a+0.592b+0.018c-5.710d+0.682e-0.047f+0.901g,

[0050] Among them, a is GRIK1 Gene expression in tumor tissues,

[0051] b is ROS1 Gene expression in tumor tissues,

[0052] c is PCDHGA4 Gene expression in tumor tissues,

[0053] d is OLFM4 Gene expression in tumor tissues,

[0054] e is ATP13A5 Gene expression in tumor tissues,

[0055] f is MYO3B Gene expression in tumor tissues,

[0056] g is IL37 Gene tumor tissue expression;

[0057] Result output module: Calculate the patient's risk score. The higher the score, the worse the prognosis.

[0058] More preferably, in step (3), the median risk score of 0.036789 is used as a threshold, and those above the threshold are high risk, and those below the threshold are low risk, thereby predicting the prognosis of gastric cancer patients.

[0059] The expression level of gene tumor tissue is calculated as per kilobase per million reads (FPKM): FPKM is the number of reads mapped to the gene divided by the total number of reads, and normalized by considering the gene length, so that the expression levels of different genes and different samples can be compared, thus avoiding expression errors caused by different sequencing depths or gene length differences. The FPKM calculation formula is as follows:

[0060] .

[0061] Beneficial effects of the present invention:

[0062] 1. The present invention integrates the overall survival data of 99 patients with gastric adenocarcinoma from Zhejiang Cancer Hospital, screens the genes GRIK1, ROS1, PCDHGA4, OLFM4, ATP13A5, MYO3B, and IL37 as prognostic markers for gastric adenocarcinoma, and constructs a risk assessment model based on GRIK1, ROS1, PCDHGA4, OLFM4, ATP13A5, MYO3B, and IL37, and verifies the accuracy of the model. The present invention helps to better predict the prognosis of patients with gastric adenocarcinoma, effectively assess the prognostic risks of different patients, intervene early, and bring great help to guide the clinical treatment of the disease, thereby improving the 5-year survival rate of patients with gastric adenocarcinoma.

[0063] 2. The present invention uses the Lasso regression algorithm, which has many advantages. First, the variable selection ability is strong: the Lasso method can shrink the coefficients of some irrelevant or weakly correlated variables to zero, thereby realizing the selection of variables and avoiding the overfitting problem. Secondly, sparse solution: due to the constraint mechanism of the Lasso method, it tends to produce sparse solutions, that is, there are many zero values ​​in the model coefficients. This sparsity makes the model more concise and more interpretable. In addition, the parameter adjustment is simple: the constraint parameter in the Lasso method can be adjusted by methods such as cross-validation, which is very convenient.

[0064] 3. The risk assessment model of the present invention has high prediction accuracy and universal applicability, which is significantly better than other gastric adenocarcinoma prognosis methods in the prior art, and is also significantly better than other models constructed during the research process. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] Figure 1 The forest plot of univariate COX analysis shows the genes with greater correlation with the prognosis of gastric adenocarcinoma screened from the data set.

[0066] Figure 2 The final number of genes is selected in Lasso regression by evaluating the fitting error.

[0067] Figure 3 This is the Lasso regression coefficient distribution diagram. By introducing a penalty term, the seven genes with the greatest correlation with gastric adenocarcinoma are displayed.

[0068] Figure 4 The time-dependent ROC curve shows the accuracy of predictions of different survival time models.

[0069] Figure 5 The ROC curve shows the overall prediction accuracy of this model.

[0070] Figure 6is the distribution of risk scores, where p=4.2e-05 means the p value is 0.000042; OS represents survival status, OS of 1 means death, and OS of 0 means survival.

[0071] Figure 7 The Kaplan-Meier survival curve shows the difference in survival rate between the high-risk group and the low-risk group.

[0072] Figure 8 This is the ROC curve diagram of single genes GRIK1, ROS1, PCDHGA4, OLFM4, ATP13A5, MYO3B, and IL37 for predicting patient prognosis. DETAILED DESCRIPTION Example 1

[0073] 1. Methods

[0074] 1. Data collection:

[0075] A total of 108 patients who were treated in Zhejiang Cancer Hospital were included. Patients with non-adenocarcinoma were excluded, resulting in 99 gastric adenocarcinoma cases. Transcriptome sequencing was performed on gastric adenocarcinoma tumor tissue samples from these 99 patients as the data set.

[0076] 2. Screening of prognostic markers:

[0077] In the data set, 198 differentially expressed genes were screened by differential analysis, and then Cox regression was used to further screen the genes. P < 0.2 was used as the threshold for screening differentially expressed genes. It was found that 30 of the 198 differentially expressed genes were associated with the prognosis of gastric adenocarcinoma patients ( Figure 1 ). Then, Lasso regression was used to introduce L1 regularization terms to constrain the coefficients of the model and compress the coefficients of some variables to zero, so as to perform feature selection. It was found that the expression of 7 genes among the above 30 genes was highly correlated with the overall survival rate of patients with gastric adenocarcinoma, and these 7 genes were finally selected as risk markers.

[0078] 3. Model establishment:

[0079] Based on the linear correlation between the regression coefficient Coef generated by the Lasso regression model and the risk marker genes, a prediction model for 7 prognosis-related genes was established.

[0080] 4. Risk scoring formula:

[0081] Risk score = (-0.782×GRIK1 gene expression in tumor tissue) + (0.592×ROS1 gene expression in tumor tissue) + (0.018×PCDHGA4 gene expression in tumor tissue) + (-5.710×OLFM4 gene expression in tumor tissue) + (0.682×ATP13A5 gene expression in tumor tissue) + (-0.047×MYO3B gene expression in tumor tissue) + (0.901×IL37 gene expression in tumor tissue).

[0082] 5. Risk classification and verification of the accuracy of risk models:

[0083] According to the median of the risk score in the dataset, the dataset was divided into high-risk group and low-risk group, and the ROC curve of the patients was drawn by the R package “survivalROC”, and the area under the curve was calculated to verify the accuracy of the model.

[0084] 2. Results

[0085] 1. The predicted risk model is obtained based on Lasso regression analysis:

[0086] Lasso regression analysis was applied, and by adding a penalty term, 7 genes with the greatest correlation were screened at the point where the partial likelihood deviation was the smallest, and the Coef (coefficient) values ​​were obtained respectively ( Figure 2 , Figure 3 ), in order to construct the risk model and risk scoring formula.

[0087] The calculation is as follows: risk score = (-0.782 × GRIK1 gene tumor tissue expression) + (0.592 × ROS1 gene tumor tissue expression) + (0.018 × PCDHGA4 gene tumor tissue expression) + (-5.710 × OLFM4 gene tumor tissue expression) + (0.682 × ATP13A5 gene tumor tissue expression) + (-0.047 × MYO3B gene tumor tissue expression) + (0.901 × IL37 gene tumor tissue expression).

[0088] A higher risk score indicates a poor prognosis, while a lower score indicates a better prognosis. The median risk score calculated based on the training model is 0.036789. Patients with a risk score higher than this value are defined as high-risk patients. The higher the score, the worse the prognosis. Patients with a risk score lower than this value are defined as low-risk patients. The lower the score, the better the prognosis.

[0089] The expression of gene in tumor tissue is calculated as per kilobase per million reads (FPKM): FPKM is the number of reads mapped to the gene divided by the total number of reads and normalized by considering the gene length. This method can eliminate the influence of gene length and sequencing depth, making the comparison between different genes more fair. The formula is:

[0090] ,

[0091] Among them, GRIK1, OLFM4, and MYO3B were negatively correlated with patient survival, while ROS1, PCDHGA4, ATP13A5, and IL37 were positively correlated with patient survival, and their roles in increasing risk are shown in Table 1 .

[0092] Table 1. Coefficients of seven genes in the model

[0093] Gene GRIK1 ROS1 PCDHGA4 OLFM4 ATP13A5 MYO3B IL37 Coef -0.782 0.592 0.018 -5.710 0.682 -0.047 0.901

[0094] 2. Dataset risk scoring:

[0095] The risk scores of all patients in the training set were calculated, and the median of all patient scores was used as the threshold (0.036789). Patients with scores higher than the median were divided into the high-risk group, and patients with scores lower than the median were divided into the low-risk group. Statistical analysis found that there was a significant difference in the scores between the high-risk group and the low-risk group (P<0.001). Figure 6 ). Kaplan-Meier curve analysis showed that the survival rate of patients in the high-risk group was lower than that in the low-risk group (P=0.008) ( Figure 7 ), indicating that the joint model can significantly distinguish high-risk and low-risk patient groups. When the seven genes are used alone to predict patient prognosis, their performance is poor and the prediction accuracy is low ( Figure 8 ), and the application of the combined model composed of 7 key molecules can greatly improve the accuracy of patient prognosis prediction, and the area under the ROC curve of overall survival rate is 0.76 ( Figure 5 ), indicating that the model has good performance. The areas under the ROC curve for measuring 1-year, 5-year, and 7-year survival rates were 0.780, 0.786, and 0.858, respectively ( Figure 4 ), further indicating that the model has good predictive ability at different disease time points, verifying its potential and reliability in clinical applications.

Claims

1. A combination of molecular markers related to the prognosis of gastric adenocarcinoma, characterized in that: Depend on GRIK1 , ROS1 , PCDHGA4 , OLFM4 , ATP13A5 , MYO3B and IL-37 These 7 genes.

2. Use of a reagent for detecting the gene expression level of the gastric adenocarcinoma prognosis-related molecular marker combination according to claim 1 in the preparation of a gastric adenocarcinoma prognosis risk prediction product.

3. The use according to claim 2, characterized in that: Prognostic risk prediction for gastric adenocarcinoma includes the following steps: (1) Detection of gastric adenocarcinoma tumor tissue samples from the individual to be tested GRIK1 , ROS1 , PCDHGA4 , OLFM4 , ATP13A5 , MYO3B and IL-37 The expression levels of these 7 genes; (2) Substitute the expression value obtained in step (1) into the risk scoring formula to obtain the risk score, where the risk scoring formula is: Risk score = -0.782a+0.592b+0.018c-5.710d+0.682e-0.047f+0.901g, Among them, a is GRIK1 Gene expression in tumor tissues, b is ROS1 Gene expression in tumor tissues, c is PCDHGA4 Gene expression in tumor tissues, d is OLFM4 Gene expression in tumor tissues, e is ATP13A5 Gene expression in tumor tissues, f is MYO3B Gene expression in tumor tissues, g is IL37 Gene tumor tissue expression; (3) The higher the patient risk score calculated in step (2), the worse the prognosis.

4. Gastric adenocarcinoma prognosis risk prediction product, characterized in that: The invention comprises a reagent for detecting the gene expression level of the combination of molecular markers related to the prognosis of gastric adenocarcinoma according to claim 1.

5. The gastric adenocarcinoma prognosis risk prediction product according to claim 4, characterized in that: The reagent is a reagent used to detect the expression level of each molecular marker.

6. The gastric adenocarcinoma prognosis risk prediction product according to claim 5, characterized in that: The reagents are primers used to detect the expression levels of various molecular markers.

7. A prognostic evaluation model for gastric adenocarcinoma, characterized in that: It includes a detection module, an analysis module and a result output module, wherein Detection module: used to detect samples from individuals to be detected, and obtain the expression level of each gene in the combination of gastric adenocarcinoma prognosis-related molecular markers according to claim 1 in the samples; Analysis module: used to analyze the expression of each gene detected by the detection module, and substitute the obtained expression value into the risk scoring formula to obtain the risk score, where the risk scoring formula is: Risk score = -0.782a+0.592b+0.018c-5.710d+0.682e-0.047f+0.901g, Among them, a is GRIK1 Gene expression in tumor tissues, b is ROS1 Gene expression in tumor tissues, c is PCDHGA4 Gene expression in tumor tissues, d is OLFM4 Gene expression in tumor tissues, e is ATP13A5 Gene expression in tumor tissues, f is MYO3B Gene expression in tumor tissues, g is IL37 Gene tumor tissue expression; Result output module: Calculate the patient's risk score. The higher the score, the worse the prognosis.

Citation Information

Patent Citations

  • Gastric adenocarcinoma marker Drosha protein and applications thereof

    CN106370852A

  • SiRNA for specifically inhibiting OLFM4 gene expression and application of siRNA

    CN111560376A